引用本文:[点击复制]
[点击复制]
【打印本页】 【在线阅读全文】【下载PDF全文】 查看/发表评论下载PDF阅读器关闭

←前一篇|后一篇→

过刊浏览    高级检索

本文已被:浏览 98次   下载 15 本文二维码信息
码上扫一扫!
粪便钙卫蛋白与肠易激综合征患者临床特征的相关性
邢晨,潘逼然,单晶,郭元彪,孙晓滨
0
(西南医科大学附属医院消化内科;成都市第三人民医院实验医学研究部;成都市第三人民医院消化内科)
摘要:
【摘要】目的 探讨粪便钙卫蛋白(FC)与肠易激综合征(IBS)的临床特征之间的关系。方法 收集2017年10月~〖JP〗12月成都市第三人民医院消化内科门诊结肠镜检查无异常且符合罗马Ⅳ诊断标准的IBS患者30例(IBS组),收集同期健康对照者30例,以酶联免疫吸附法定量检测粪便的钙卫蛋白含量,分析粪便钙卫蛋白与肠易激综合征患者临床特征的相关性。结果 IBS患者粪便中钙卫蛋白含量与健康人比较无差异(P<005)。粪便钙卫蛋白IBS患病时间、腹痛>6个月、解稀水便有相关性(P<005)。与健康人群相比,IBS患病开始即出现粪便钙卫蛋白水平有显著降低(t=-2621,P=0012),而1~5年IBS患者粪便钙卫蛋白水平更降低(t=344,P=0002)。同时,腹痛>6个月的患者FC有显著增加。结论 粪便钙卫蛋白与IBS患者的患病时间、腹痛6个月以上、解稀水便等临床特征具有相关性。
关键词:  钙卫蛋白  肠易激综合征  炎性肠病  腹痛  腹泻  便秘
DOI:
基金项目:国家自然基金面上项目(81270465);四川省科技厅项目(2014JY0017);成都市科技局课题(2015 HM01 00377 SF)
Correlation between fecal calprotectin and clinical features of patients with irritable bowel syndrome
XING Chen,PAN Biran,SHAN Jing,GUO Yuanbiao,SUN Xiaobin
(Department of Gastroenterology,Southwest Medical University;Department of Experimental Medicine Research, The Third People's Hospital of Chengdu;Department of Gastroenterology, The Third People's Hospital of Chengdu)
Abstract:
【Abstract】Objective The aim of this study is to explore the relationship between fecal calprotectin and clinical features of irritable bowel syndrome (IBS).Methods From October to December 2017, 30 IBS patients (IBS group) were collected from the outpatient department of gastroenterology department of Chengdu Third People's Hospital, who had no abnormal colonoscopy and met the Rome IV diagnostic standard. 30 healthy controls were collected at the same time, and the content of calprotectin in feces was quantitatively detected by enzymelinked immunosorbent assay. ResultsThere was no significant difference in the content of calprotectin between IBS patients and healthy people (P<005). However, there was a significant correlation among the time of IBS, abdominal pain >6 months and defecation (P<005). Compared with the healthy population, the level of faecal calprotectin in IBS patients decreased significantly at the beginning of the disease (t=〖CD*3/5〗2621, P=0012), while the level of faecal calprotectin in patients with IBS in 15 years decreased even more (t=344, P=0002). At the same time, FC increased significantly in patients with abdominal pain> 6 months. Conclusions Fecal calprotectin was significantly associated with IBS symptoms such as the duration of IBS, abdominal pain>6 months and watery stool.
Key words:  Calprotectin  Irritable bowel syndrome  Inflammatory bowel disease  Abdomial pain  Diarrhea  Constipation

用微信扫一扫

用微信扫一扫